FXEMPIRE
All
Ad
Corona Virus
Stay Safe, FollowGuidance
World
100,441,967Confirmed
2,154,063Deaths
72,472,923Recovered
Fetching Location Data…
Advertisement
Advertisement
Alan Farley
Pfizer

Pfizer Inc. (PFE) rallied more than 15% at the open of Monday’s U.S. session after reporting a 90% success rate with a vaccine candidate under development in collaboration with Germany’s BioNTech SE (BNTX). COVID-19 beneficiaries sold off on the news while shares of cruise ship operators, movie theaters, and airline carriers took off for the heavens. However, sellers pounced on the opening bid, dropping the pharmaceutical giant more than three points off the high.

Advertisement
Know where the Market is headed? Take advantage now with 

75% of retail CFD investors lose money

Pandemic Headwinds Likely To Persist

The high efficacy rate is good news but major obstacles are likely to delay an early end to the pandemic. For starters, an October survey indicated that just 58% of Americans will take a vaccine as soon as it’s manufactured, due to anti-vax theories and general political unrest. The 10% ineffective rate is also too high for instant relief, asking those most vulnerable to serious illnesses to ‘roll the dice’, hoping for an immune response.

Pfizer CEO Albert Bouria appeared on CNBC on Monday morning, expressing genuine enthusiasm for the compound. He believes we’re finally seeing the light at the end of the COVID-19 tunnel but warned that side effects have been reported. He also views the candidate as the ‘most significant medical advance in the past 100 years’, which seems like hyperbole, given statins, the polio vaccine, and other life-saving drugs introduced in the last century.

Advertisement

Wall Street And Technical Outlook

Wall Street has been caught ‘asleep at the wheel’ on Pfizer’s long-term outlook, posting a sluggish ‘Moderate Buy’ rating based upon 4 ‘Buy’ and 4 ‘Hold’ recommendations.  To their credit, no analysts are recommending that shareholders close positions and move to the sidelines. Price targets currently range from a low of $38 to a Street-high $53 while the stock has descended to the low target after an opening spike to $42.

Pfizer is a slow moving stock that’s underperformed since a 9-year uptrend topped out less than four points below 1999’s all-time high in 2018. This weak performance induced the keepers of the Dow Industrial Average to remove the stock last summer, in an act of near-perfect timing. It posted a four-year low in March 2000 and turned higher, stalling in the upper 30s in June. Monday’s breakout is test new support at that level, with mid-term upside limited to the mid-40s.

For a look at all of today’s economic events, check out our economic calendar.

 

Don't miss a thing!
Discover what's moving the markets. Sign up for a daily update delivered to your inbox

Trade With A Regulated Broker

  • Your capital is at risk
IMPORTANT DISCLAIMERS
The content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your own due diligence checks, apply your own discretion and consult your competent advisors. The content of the website is not personally directed to you, and we does not take into account your financial situation or needs.The information contained in this website is not necessarily provided in real-time nor is it necessarily accurate. Prices provided herein may be provided by market makers and not by exchanges.Any trading or other financial decision you make shall be at your full responsibility, and you must not rely on any information provided through the website. FX Empire does not provide any warranty regarding any of the information contained in the website, and shall bear no responsibility for any trading losses you might incur as a result of using any information contained in the website.The website may include advertisements and other promotional contents, and FX Empire may receive compensation from third parties in connection with the content. FX Empire does not endorse any third party or recommends using any third party's services, and does not assume responsibility for your use of any such third party's website or services.FX Empire and its employees, officers, subsidiaries and associates, are not liable nor shall they be held liable for any loss or damage resulting from your use of the website or reliance on the information provided on this website.
RISK DISCLAIMER
This website includes information about cryptocurrencies, contracts for difference (CFDs) and other financial instruments, and about brokers, exchanges and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and come with a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money.FX Empire encourages you to perform your own research before making any investment decision, and to avoid investing in any financial instrument which you do not fully understand how it works and what are the risks involved.
FOLLOW US